Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun Vasant Balar, Dean F. Bajorin, Bernhard J. Eigl et al.|The Lancet|2016Cited by 2.2k
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Thomas Powles, Maha Hussain et al.|The Lancet Oncology|2021Cited by 411
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic CancerDimitrios Stefanoudakis, Konstantinos G. Toutouzas, Maximos Frountzas et al.|Current Issues in Molecular Biology|2024Cited by 78
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) ConsortiumTalal El Zarif, Danai Dima, Amin H. Nassar et al.|Journal of Clinical Oncology|2023Cited by 69
The Potential Revolution of Cancer Treatment with CRISPR TechnologyDimitrios Stefanoudakis, Alexandra Drakaki, Nikhita Kathuria‐Prakash et al.|Cancers|2023Cited by 63